$NBY upturn Amex $3.20 Website http://nova
Post# of 63688
Posted On: 01/24/2016 12:26:34 PM
$NBY upturn
Amex $3.20
Website
NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova
Sales to Exceed $1.5 Million Business Wire(Mon, Jan 11)
3 Biotech Stocks Under $10 to Trade for Big Breakout
TheStreet(Fri, Jan
NovaBay Pharmaceuticals Secures $3 Million Bridge Loan
Business Wire(Thu, Jan 7)
Shares Outstanding: 3.49M
Float: 2.92M
% Held by Insiders: 19.17%
% Held by Institutions: 4.90%
Shares Short (as of Dec 31, 2015): 22.84K
Short Ratio (as of Dec 31, 2015): 0.37
Short % of Float (as of Dec 31, 2015): 0.75%
Shares Short (prior month): 19.09K
Headlines
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes topical non-antibiotic antimicrobial products for the eye care market. It operates through four segments: Dermatology, Ophthalmology, Urology, and Wound Care. The company focuses on addressing the unmet therapeutic needs of the topical anti-infective market. Its commercial products include the Neutrox family of products, including Avenova for the eye care market; Neutrophase for wound care; and CelleRx for the dermatology market. The companys products under development stage consist of Aganocide compounds, which are novel, synthetic anti-infectives designed to mimic the bodys defense against infection and developed to treat and prevent a range of local, non-systemic infections with a low likelihood of developing bacterial resistance. It has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds that cover various dermatological conditions. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
Amex $3.20
Website
NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova
Sales to Exceed $1.5 Million Business Wire(Mon, Jan 11)
3 Biotech Stocks Under $10 to Trade for Big Breakout
TheStreet(Fri, Jan
NovaBay Pharmaceuticals Secures $3 Million Bridge Loan
Business Wire(Thu, Jan 7)
Shares Outstanding: 3.49M
Float: 2.92M
% Held by Insiders: 19.17%
% Held by Institutions: 4.90%
Shares Short (as of Dec 31, 2015): 22.84K
Short Ratio (as of Dec 31, 2015): 0.37
Short % of Float (as of Dec 31, 2015): 0.75%
Shares Short (prior month): 19.09K
Headlines
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes topical non-antibiotic antimicrobial products for the eye care market. It operates through four segments: Dermatology, Ophthalmology, Urology, and Wound Care. The company focuses on addressing the unmet therapeutic needs of the topical anti-infective market. Its commercial products include the Neutrox family of products, including Avenova for the eye care market; Neutrophase for wound care; and CelleRx for the dermatology market. The companys products under development stage consist of Aganocide compounds, which are novel, synthetic anti-infectives designed to mimic the bodys defense against infection and developed to treat and prevent a range of local, non-systemic infections with a low likelihood of developing bacterial resistance. It has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds that cover various dermatological conditions. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
(0)
(0)